Contact - Recon Strategy

INSIGHTS

It was bioengineering at its best: An opinionated take on NEJM highlights for Q2 of 2025

Biopharma Product Strategy: Lessons from Over- and Under-performing Launches

A few thoughts about navigating biopharma macro scenarios

Preclinical Licensing Deals Realized Value

We use cookies

This website collects cookies to deliver better user experience and to analyze our website traffic and performance; we never collect any personal data or target you with ads.

CONTACT US

We work with U.S. and global companies

Boston Office

Seattle Office

Email Us